| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q33402700 | A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. |
| Q33378432 | A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. |
| Q33386523 | A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer |
| Q35058595 | A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321 |
| Q37601709 | Adaptive Randomization of Neratinib in Early Breast Cancer |
| Q37601722 | Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer |
| Q38089548 | Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway |
| Q91069671 | Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2 |
| Q97676721 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical T |
| Q35100279 | Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. |
| Q30882876 | Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: a case report |
| Q37132369 | Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial |
| Q38711157 | Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? |
| Q35770292 | Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer |
| Q33439441 | Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma |
| Q47137308 | Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study |
| Q35118969 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole |
| Q35168556 | Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen |
| Q36025853 | Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy |
| Q33423653 | Factitious Disorder in Crohn's Disease: Recurrent Pancytopenia Caused by Surreptitious Ingestion of 6-Mercaptopurine |
| Q36413493 | Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. |
| Q30428702 | Intersection of cardiology and oncology clinical practices |
| Q36572779 | Live, attenuated varicella zoster vaccination of an immunocompromised patient |
| Q89592800 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial |
| Q34094703 | Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? |
| Q36652690 | North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane |
| Q37724516 | Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors |
| Q36337960 | Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer |
| Q37520291 | Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. |
| Q30365919 | Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma |
| Q91580912 | Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer |
| Q37495410 | Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer |
| Q36672633 | Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer |
| Q33429255 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients |
| Q35226507 | Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors |
| Q37594553 | Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies |
| Q33414664 | Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors |
| Q37407066 | Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial |
| Q33402203 | Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma |
| Q38680172 | Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management |
| Q35755358 | Quality of life and disease understanding: impact of attending a patient-centered cancer symposium |
| Q36718403 | RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. |
| Q55017654 | SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. |
| Q30252469 | Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors |
| Q36714877 | TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression |
| Q37997377 | The impact of obesity on breast cancer: a retrospective review. |
| Q37074325 | Trastuzumab-induced cardiotoxicity: heart failure at the crossroads |
| Q37790308 | Triple-negative breast cancers: unique clinical presentations and outcomes |
| Q33614238 | Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer |
| Q36045822 | Use of liposomal anthracyclines in Kaposi's sarcoma |
| Q33793932 | Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer |
Search more.